Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Allopurinol
Drug ID BADD_D00076
Description Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Indications and Usage Allopurinol is indicated in [FDA label]: 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Marketing Status approved
ATC Code M04AA01
DrugBank ID DB00437
KEGG ID D00224
MeSH ID D000493
PubChem ID 135401907
TTD Drug ID D04KYY
NDC Product Code 23155-694; 43063-975; 55154-5534; 60687-688; 62135-516; 66064-1043; 69967-009; 70710-1209; 70934-681; 71610-676; 72189-437; 43063-934; 55154-5454; 58118-1156; 60687-677; 60760-656; 61919-748; 63187-463; 0378-0181; 67296-1314; 68083-380; 68788-8364; 70199-031; 71610-194; 0603-2116; 51927-0070; 51927-1915; 16571-885; 16714-042; 16729-135; 43353-186; 51655-082; 0378-0137; 66267-665; 67544-313; 68071-2997; 68788-8458; 69967-008; 70199-016; 70518-3660; 70710-1210; 0603-2115; 71610-678; 63629-2113; 63739-410; 66064-1044; 68788-6323; 71610-681; 63552-151; 68108-0212; 51079-206; 51655-968; 53002-4821; 53489-157; 55111-729; 63739-796; 68071-2616; 68071-2660; 68788-7383; 70934-882; 71205-208; 71610-064; 0591-5544; 49452-0008; 65015-606; 66064-2100; 16571-883; 16714-041; 43353-501; 51655-523; 51655-782; 53002-4820; 55700-947; 62584-988; 63187-240; 63629-2112; 70771-1126; 0591-5543; 71610-253; 0615-8385; 57451-1166; 16714-576; 23155-693; 43063-976; 51655-945; 55154-7981; 60760-139; 62584-713; 63629-7908; 67457-187; 67457-978; 67544-736; 70199-033; 71205-377; 72162-1150; 0904-7041; 17351-0041; 36974-0018; 16571-884; 29300-349; 50090-5168; 51079-205; 61919-471; 62135-517; 63629-2111; 63629-8020; 65219-380; 67296-1265; 69315-291; 70518-1806; 70518-3289; 70771-1127; 70934-979; 71335-0467; 71335-1656; 71335-9634; 71610-197; 72189-417; 80425-0206; 0904-6572; 29300-350; 50090-4662; 68071-2926; 69315-292; 70199-032; 70518-3704; 71205-049; 71335-9641; 71335-9676; 72162-1149; 49711-0113; 63552-150; 65977-0124; 16714-577; 16729-134; 43063-935; 53489-156; 55700-935; 60760-134; 68788-8337; 68788-8424; 70199-015; 70518-0451; 71335-0112; 14445-001; 72375-0007; 50090-0044; 50090-5194; 55111-730; 55154-2338
UNII 63CZ7GJN5I
Synonyms Allopurinol | Uribenz | Allopurin | Allorin | Allpargin | Allural | Pan Quimica | Apulonga | Apurin | Atisuril | Bleminol | Caplenal | Capurate | Cellidrin | Embarin | Suspendol | Foligan | Hamarin | Lopurin | Lysuron | Jenapurinol | Milurit | Milurite | Novopurol | Uripurinol | Urosin | Urtias | Xanthomax | Uridocid | Xanturic | Zygout | Zyloprim | Zyloric | Pureduct | Purinol | Progout | Remid | Rimapurinol | Roucol | Tipuric | Allohexal | Allohexan | Alloprin
Chemical Information
Molecular Formula C5H4N4O
CAS Registry Number 315-30-0
SMILES C1=NNC2=C1C(=O)NC=N2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Angioimmunoblastic T-cell lymphoma16.17.05.001; 01.11.05.001--Not Available
Aplasia03.02.01.002; 08.03.04.003--Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.001--Not Available
Aplastic anaemia01.03.03.002--Not Available
Apnoea22.02.01.001--
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Azotaemia20.01.01.001--Not Available
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene